Targeting the ATX–LPA pathway holds therapeutic potential because this signaling axis may promote the development of neurodegenerative diseases through multiple mechanisms involving mitochondrial dysfunction, oxidative stress, inflammation, and other processes. The gene discussed is LPA; the disease is neurodegenerative disease.